1+ week, 5+ day ago   (1476+ words) Eventually, however, many patients reach a point at which endocrine-based strategies have been exhausted and chemotherapy becomes necessary. That is the setting in which izalontamab brengitecan (iza-bren; BL-B01D1) is now generating considerable interest. On August 26, 2026, Sichuan Biokin Pharmaceutical announced that…...

2+ week, 5+ day ago   (229+ words) Victor Moreno, Director of Clinical Research at START Madrid FJD, shared on LinkedIn: “PD-1/VEGF bispecific antibodies are moving beyond lung cancer. Could triple-negative breast cancer be another setting where this makes sense? A recently published multicentre phase 2 trial evaluated…...

2+ week, 5+ day ago   (495+ words) The study, published in The Breast, evaluated whether chemotherapy selection supported by the Oncotype DX recurrence score was associated with differences in overall survival compared with physician-directed chemotherapy decisions without genomic testing. The findings highlight the growing role of genomic…...

2+ week, 6+ day ago   (165+ words) Kefah Mokbel, Chair of Breast Cancer Surgery at London Breast Institute, shared on LinkedIn: “New study: MRI response may help personalize internal mammary node radiotherapy after neoadjuvant therapy A new study by Yushuo Peng and colleagues, published online in International…...

3+ week, 4+ day ago   (93+ words) Sara Tolaney Leads Study on Breast Cancer Patients With Response After Chemo With Pembrolizumab Oncodaily Sara Tolaney Leads Study on Breast Cancer Patients With Response After Chemo With Pembrolizumab Alliance for Clinical Trials in Oncology shared on X: “Sara Tolaney of…...

4+ week, 1+ day ago   (939+ words) Affiliation: Europa Donna Serbia – The Serbian Breast Cancer Forum Role: National Delegate, Europa Donna – The European Breast Cancer Coalition Every breast cancer diagnosis begins with uncertainty. For many women, the greatest challenge is not only understanding the diagnosis itself, but…...

4+ week, 2+ day ago   (373+ words) Shom Goel, Associate Professor at University of Melbourne, shared on LinkedIn: ”Delighted to share our new paper, published today in Nature, led by the outstanding April Watt and Antonio Ahn at the Peter MacCallum Cancer Centre and the University of…...

1+ mon, 1+ day ago   (250+ words) Ada Waks: Therapeutic Strategy for CDK4/6i-Resistant HR+ Metastatic Breast Cancer / Ada Waks, Adrienne G. Waks, Amy Williams, Ann Partridge, Anna Mae Frey,, Ada Waks, Adrienne G. Waks, Amy Williams, Ann Partridge, Anna Mae Frey, Ashka Patel, Barbara LeStage, Breast Cancer, cancer, Dana-Farber’s…...

1+ mon, 1+ day ago   (234+ words) Mathieu Lupien, Senior Scientist at University Health Network, shared on LinkedIn: “How do you find what drives a cancer subtype that is defined by what it doesn’t have? That was the challenge Shalini Bahl, Nergiz Dogan-Artun and an incredible team…...

1+ mon, 3+ day ago   (142+ words) Oncodaily Charles Jiang and Paolo Tarantino: Requirements for Validating ctDNA and MRD Biomarker Strategies in Breast Cancer Charles Jiang, Assistant Professor medical oncologist at UT Southwestern Medical Center, shared an update from Paolo Tarantino, Visiting Professor at McGill University Health…...